Search results
Kimberly Payne, PhD (1961-2020) Dr. Kimberly Payne’s lifelong dedication to the health and wellness of children developed into a career in medical research spanning three decades. Inspired by the promise of translational research, the discovery of new therapies, and the hope for a cure to pediatric
Aug 21, 2018 · Research. Right place, right time for researcher examining leukemia’s high rate in Hispanic children. By Kimberly Payne - August 21, 2018. Facebook X LinkedIn. Kimberly Payne, PhD, is the CEO of Elf Zone, Inc. and director of translational research at Loma Linda University School of Medicine.
Education. 1991 - 1995. 1998 - 2003. Experience: Loma Linda University, School of Medicine · Location: Loma Linda · 170 connections on LinkedIn. View Kimberly Payne’s profile on LinkedIn,...
- 171
- 171
- Loma Linda University, School of Medicine
- Loma Linda, California
- Collaboration with The Children's Oncology Group
- Treatment Through Young Adulthood
- Health Disparities in Pediatric Leukemia
- Elf Zone, Inc.
- Collaboration with The Cancer Health Disparities Program
Our pediatric clinical research team, led by Dr. Albert Kheradpour, works closely with the Children's Oncology Group to assure that our patients have opportunities to participate in clinical trials that give them access to the most cutting-edge treatments available. Historically, Loma Linda University Children's Hospitalhas been among the top 10 pe...
Many pediatric patients develop cancer during adolescence and will continue treatment during the transition to young adulthood. Because treatment response and toxicity can change with age, the adolescent and young adult (AYA) population offers unique challenges. Loma Linda University's Children's Hospital and Medical Center have a unique ability to...
Loma Linda University Health is a national leader in pediatric cancer clinical trials and a large portion of our patient base is Hispanic. Because of this, we're uniquely positioned to both study B-ALL and eventually end health disparities surrounding it. We have the resources necessary to facilitate research and translate results into impactful pa...
This research also works in tandem with program director Kim Payne's (In Memorium) biotech company, Elf Zone, Inc. Elf Zone's specific goal is to translate the program's research into a clinically viable treatment. In this way, treatments for B-ALL become available as efficiently as possible. Created in partnership with the LLU biotech incubator, N...
The Pediatric Leukemia Research Program shares a large component with another one of our cancer research programs, the Cancer Health Disparities Program. Because a specific subtype of aggressive B-ALL disproportionately affects Hispanic children, there is a significant opportunity to reduce health disparity in our community. Work on unraveling this...
Kimberly PAYNE | Cited by 2,963 | of Loma Linda University, CA | Read 167 publications | Contact Kimberly PAYNE
Oct 11, 2017 · Kimberly Payne, PhD, CEO of Elf Zone and director of translational research at Loma Linda University School of Medicine, says the grant will help develop a promising new treatment for B-ALL. The discovery that led to the grant came as an ironic surprise to Payne and colleagues.
Sep 19, 2014 · Kimberly Payne, Ph.D., Associate Professor and Director of Translational Research at the Loma Linda University School of Medicine in Loma Linda, CA, is funded by an NCI-CRCHD R21 grant to investigate the genetic underpinning for this disparity.
